NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis

Phathom Pharmaceuticals, Inc. (PHAT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PHAT

$7.03

−$0.28 (−3.83%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PHAT with… →

PHAT Key Statistics

As of Oct 21, 2026
Trading
Open
$7.31
Previous Close
$7.31
Day's Range
7.01–7.48
52-Week Range
6.52–18.31
Volume
784.16K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
$568.73M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.37
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.26
Financials (FY)
Revenue (FY)
$175.11M+216.93%
Net Income (FY)
−$221.25M
Profit marginThe share of revenue left as profit after all costs and taxes.
−41.34%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.90M
1-Year Return
−49.79%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
1.40M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PHAT closed at $7.03, −49.79% over 1 year.

Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of $568.73M.

In fiscal 2025, PHAT reported revenue of $175.11M.

PHAT Stock Return by Calendar Year

Phathom Pharmaceuticals, Inc. (PHAT) return since Oct 2019: what $10,000 became

1 year
$10,000 $5,021
−49.79%
5 years
$10,000 $2,383
−76.17%
Since Oct 2019
$10,000 $2,858
−71.42%

If you had invested $10,000 in Phathom Pharmaceuticals, Inc. (PHAT) at the close on October 25, 2019, the earliest close on record here, it would have been worth $2,858 at the close on October 21, 2026: −71.42% in total, −16.41% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−57.63%
2025+104.31%
2024−11.06%
2023−18.63%
2022−42.96%
2021−40.79%
2020+6.68%
2019 (partial year)+26.59%

As of October 21, 2026.

PHAT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$175.11M−$221.25M−126.3%
2024$55.25M−$334.33M−605.1%
2023$682.00K−$201.59M−29,558.9%
2022$0.00−$197.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$175.11M$152.51M−$159.99M−$221.25M−126.3%
2024$55.25M$47.28M−$277.47M−$334.33M−605.1%
2023$682.00K$515.00K−$167.31M−$201.59M−29,558.9%
2022$0.00$0.00−$172.44M−$197.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PHAT Valuation vs Biotechnology Median

Median of 608 stocks
MetricPHATBiotechnology medianvs median
P/S ratio2.3713.300.2x the median
Profit margin−41.34%−38.31%3.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Phathom Pharmaceuticals, Inc. (PHAT) is capitalised at $568.73M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 371.

PHAT last closed at $7.03 on October 21, 2026. That is −$0.28 (−3.83%) against the previous close. Over the past 52 weeks the price has ranged from $6.52 to $18.31. The latest close sits 7.82% above that 52-week low.

Financial Health

In fiscal 2025, Phathom Pharmaceuticals, Inc. reported revenue of $175.11M. That is +216.93% against the prior fiscal year, when revenue was $55.25M. The same year closed with a net loss of $221.25M. Profit margin runs at −41.34%. That is 3 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −1.26.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $175.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 6.7. The price-to-sales ratio is 2.37. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −49.79%. Across 5 years the annualized return works out at −24.94%. Beta against the wider market is reported at 0.5. Daily returns over the trailing 7 years annualize to a volatility of 91.1%.

Growth & Income

The record shows no dividend for PHAT.

So far in 2026 the total return is −57.63%. The strongest complete calendar year on file is 2025 at +104.31%; the weakest is 2022 at −42.96%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Phathom Pharmaceuticals, Inc. (PHAT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Phathom Pharmaceuticals, Inc. PHAT $568.73M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Phathom Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Visit website →